Inclusion Criteria:  Atopic dermatitis according to the Hanifin and Rajka criteria. Validated Investigator Global Assessment score of 3 or 4 out of 4 Eczema Area and Severity Index (EASI) score ≥7.1 Moderate to severe disease as above despite an adequate trial of topical therapy.  Exclusion Criteria:  Treatment with phototherapy or oral systemic immune-modulating agents (cyclosporine, methotrexate, azathioprine, mycophenolate) less than 30 days before baseline. Treatment with systemic biologic (dupilumab) or experimental therapeutic less than 90 days before baseline. Current treatment with oral or intramuscular corticosteroids within 30 days prior to baseline. Topical, intralesional or inhaled corticosteroids are allowed. Participating in a clinical trial assessing an investigational agent for atopic dermatitis (topical, systemic or device) within 90 days prior to enrollment.